Venclexta has been on the market since 2016 for CLL, initially for 17p-mutated cases, and since 2019 has been used as a first ...

Venclexta/Venclyxto is being developed by AbbVie and Roche. It is jointly commercialised by AbbVie and Genentech, a member of the Roche Group, in the US, and commercialised by AbbVie outside of ...

AbbVie is seeking a new way to fight chronic lymphocytic leukemia by combining its oncology drug Venclexta with another ...

AbbVie submitted a supplemental new drug application for Venclexta plus Calquence treatment in previously untreated chronic ...

After establishing Venclexta as a treatment for chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML), AbbVie and Roche were hoping to demonstrate the med's promise in a subset of mul ...

Roche Holding AG RHHBY announced new data from the phase III MURANO study on Venclexta/Venclyxto (venetoclax) in patients with previously treated chronic lymphocytic leukemia (CLL) at the American ...

Venclexta, the AbbVie- and Roche-developed treatment for leukemia, may not prove effective for another form of blood cancer, multiple myeloma. AbbVie reported Friday morning that data from a Phase ...

By Reuters December 4, 20186:13 AM UTCUpdated ago Dec 4 (Reuters) - Roche Holding AG: * NEW VENCLEXTA/VENCLYXTO DATA DEMONSTRATE DEEP RESPONSES IN TWO OF MOST COMMON TYPES OF LEUKAEMIA ...

June 4 (Reuters) - ROCHE HOLDING AG: * PIVOTAL PHASE III CLL14 RESULTS FOR VENCLEXTA/VENCLYXTO IN COMBINATION WITH GAZYVA/GAZYVARO FOR CHRONIC LYMPHOCYTIC LEUKAEMIA PRESENTED AT ASCO 2019 AND ...

The FINANCIAL — Roche announced on April 12 that the U.S. Food and Drug Administration (FDA) granted accelerated approval to Venclexta (venetoclax) for the treatment of people with chronic ...

Roche plans to present the study outcomes at the American Society of Clinical Oncology Annual Meeting to be held in June 2019. Venclexta is co-developed by AbbVie ABBV and Genetech, a unit of Roche.